X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA BIOCON LTD PLETHICO PHARMA/
BIOCON LTD
 
P/E (TTM) x -1.1 76.7 - View Chart
P/BV x 0.0 7.2 0.2% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PLETHICO PHARMA   BIOCON LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
BIOCON LTD
Mar-17
PLETHICO PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs3951,162 34.0%   
Low Rs31483 6.5%   
Sales per share (Unadj.) Rs604.4194.6 310.7%  
Earnings per share (Unadj.) Rs32.534.4 94.4%  
Cash flow per share (Unadj.) Rs51.348.3 106.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs473.6241.9 195.8%  
Shares outstanding (eoy) m34.08200.00 17.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.2 8.3%   
Avg P/E ratio x6.623.9 27.5%  
P/CF ratio (eoy) x4.217.0 24.4%  
Price / Book Value ratio x0.53.4 13.2%  
Dividend payout %02.9 0.0%   
Avg Mkt Cap Rs m7,262164,440 4.4%   
No. of employees `000NA9.2 0.0%   
Total wages/salary Rs m1,5967,470 21.4%   
Avg. sales/employee Rs ThNM4,213.9-  
Avg. wages/employee Rs ThNM809.0-  
Avg. net profit/employee Rs ThNM745.2-  
INCOME DATA
Net Sales Rs m20,59838,911 52.9%  
Other income Rs m3861,571 24.6%   
Total revenues Rs m20,98440,482 51.8%   
Gross profit Rs m2,8189,795 28.8%  
Depreciation Rs m6422,772 23.2%   
Interest Rs m1,593260 612.8%   
Profit before tax Rs m9698,334 11.6%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,616 -8.6%   
Profit after tax Rs m1,1076,881 16.1%  
Gross profit margin %13.725.2 54.3%  
Effective tax rate %-14.319.4 -73.7%   
Net profit margin %5.417.7 30.4%  
BALANCE SHEET DATA
Current assets Rs m18,87740,477 46.6%   
Current liabilities Rs m11,89616,783 70.9%   
Net working cap to sales %33.960.9 55.7%  
Current ratio x1.62.4 65.8%  
Inventory Days Days3660 60.3%  
Debtors Days Days19883 238.8%  
Net fixed assets Rs m9,86145,073 21.9%   
Share capital Rs m3411,000 34.1%   
"Free" reserves Rs m12,33147,377 26.0%   
Net worth Rs m16,13948,377 33.4%   
Long term debt Rs m4,70621,082 22.3%   
Total assets Rs m33,14693,942 35.3%  
Interest coverage x1.633.1 4.9%   
Debt to equity ratio x0.30.4 66.9%  
Sales to assets ratio x0.60.4 150.0%   
Return on assets %8.17.6 107.2%  
Return on equity %6.914.2 48.2%  
Return on capital %12.312.6 97.5%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40212,988 33.9%   
Fx outflow Rs m3,1847,899 40.3%   
Net fx Rs m1,2195,089 23.9%   
CASH FLOW
From Operations Rs m2,4376,400 38.1%  
From Investments Rs m-6,265-4,985 125.7%  
From Financial Activity Rs m2,490-1,775 -140.3%  
Net Cashflow Rs m-1,337-473 282.7%  

Share Holding

Indian Promoters % 82.7 40.4 204.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 4.3 8.4 51.2%  
FIIs % 5.5 10.7 51.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 19.9 37.7%  
Shareholders   10,665 109,995 9.7%  
Pledged promoter(s) holding % 85.7 0.0 214,350.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA LTD  PFIZER  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - GSK PHARMA COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS